{"filing":{"accession_number":"0001104659-26-068002","cik":"0001737953","ticker":"REPL","company_name":"Replimune Group, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"tm2615980d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"events":[{"id":8041,"run_id":7057,"accession_number":"0001104659-26-068002","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The disclosure announces a resubmission of a Biologics License Application (BLA) for RP1 in combination with nivolumab following FDA communications. This represents a material regulatory development for a clinical-stage biopharmaceutical company, as BLA resubmission decisions directly impact the path to commercialization and investor valuation. While not a traditional earnings release, exec change, or M\u0026A event, the regulatory milestone is material to investors assessing the company's pipeline progress and FDA approval prospects.","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2598,"accession_number":"0001104659-26-068002","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a resubmission of a Biologics License Application (BLA) for RP1 in combination with nivolumab following FDA communications. This represents a material regulatory development for a clinical-stage biopharmaceutical company, as BLA resubmission decisions directly impact the path to commercialization and investor valuation. While not a traditional earnings release, exec change, or M\u0026A event, the regulatory milestone is material to investors assessing the company's pipeline progress and FDA approval prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:06:07.552941+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2598,"accession_number":"0001104659-26-068002","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a resubmission of a Biologics License Application (BLA) for RP1 in combination with nivolumab following FDA communications. This represents a material regulatory development for a clinical-stage biopharmaceutical company, as BLA resubmission decisions directly impact the path to commercialization and investor valuation. While not a traditional earnings release, exec change, or M\u0026A event, the regulatory milestone is material to investors assessing the company's pipeline progress and FDA approval prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:06:07.552941+00:00","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-05-29"}]}